The results are meaningful because all five of the psychological disorders mentioned above are associated with high levels of functional and psychosocial disability in chronic PTSD patients [3, 4, 6, [12] [13] [14] [15] [16] [64] [65] [66] [67] [68] [69] , and most are reported to predict greater refractoriness to routine therapy in individuals diagnosed with PTSD [17, [70] [71] [72] [73] . For example, PTSD patients who report somatic symptoms also report higher overall PTSD symptoms [15, 64] and a higher frequency of depression [64, 74] . Patients with co-morbid PTSD and obsessive-compulsive behavior have been found to have a poorer response to cognitive behavioral therapy than those diagnosed with PTSD alone [73] . Co-morbid PTSD/depression appears to predict greater refractoriness to pharmacotherapy, greater symptom severity, lower levels of functioning and rates of recovery, and increased disability and potential of suicide [4, 6, [65] [66] [67] . Like depression, anxiety symptoms are associated with lower quality-of-life estimates and greater refractoriness to routine pharmacotherapy in PTSD patients [3, 68] . Hostility, which according to a meta-analysis of 39 studies is significantly elevated in individuals with PTSD [16] , is linked to adverse health outcomes, including cardiac death [69] . In the present study, XTJYF also appears to improve the sleep quality of these PTSD patients; sleep disturbances are among the most treatment-resistant symptoms of PTSD [75] . All of these symptoms are likely to contribute to alcohol and drug abuse [76, 77] as well as suicidal ideation [78] .